Colestipol and Cholestyramine Resin: Comparative Effects in Familial Type II Hyperlipoproteinemia

JAMA: The Journal of the American Medical Association

Volumn 222, Issue 6, 1972, Pages 676-681

  Glueck, Charles J ^a   Ford, Starr ^a   Scheel, Deborah ^a   Steiner, Paula ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; COLESTYRAMINE; ETHER DERIVATIVE; ION EXCHANGE RESIN; LIPOPROTEIN; PLACEBO; POLYAMINE; TRIACYLGLYCEROL;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD; BLOOD PROTEIN DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DIET THERAPY; FEMALE; GENETICS; HUMAN; HYPERLIPIDEMIA; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TIME;

ANALYSIS OF VARIANCE; BILE ACIDS AND SALTS; BLOOD PROTEIN DISORDERS; CHOLESTEROL; CHOLESTYRAMINE; CLINICAL TRIALS; COMPARATIVE STUDY; DIET THERAPY; ETHERS, CYCLIC; FEMALE; HUMAN; HYPERLIPIDEMIA; ION EXCHANGE RESINS; LIPOPROTEINS; MALE; PLACEBOS; POLYAMINES; TIME FACTORS; TRIGLYCERIDES;

EID: 0015496271     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1972.03210060032007     Document Type: Article

References (28)

1. Hashim SA, VanItallie TB: Cholestyramine resin therapy for hypercholesterolemia. JAMA 192:289-293, 1965.
2. Fallon HJ, Woods JW: Response of hyperlipoproteinemia to cholestyramine resin. JAMA 204:1161-1164, 1968.
3. Howard AN, Hyams DE: Combined use of Clofibrate and cholestyramine or DEAE Sephadex in hypercholesterolemia. Brit Med J 3:25-26, 1971.
4. Levy RI, Fredrickson DS, Kwiterovich PO, et al: Normalization of lipids in “Familial Hypercholesterolemia.” Circulation 40(suppl 3):15, 1969.
5. Casdorph HR: Treatment of the hyperlipidemic states with special emphasis on the place of cholestyramine in therapy. Angiology 21:654-660, 1970.
6. Parkinson TM: Hypolipidemic effects of orally administered dextran and cellulose anion exchangers in cockerels and dogs. J Lipid Res 8:24-29, 1967.
7. Eastwood MA, Girdwood RH: Lignin-A bile acid sequestrating agent. Lancet 2:1170-1172, 1968.
8. Fahrenbach MJ, Riccardi BA, Grant WC: Hypocholesterolemic activity of mucilaginous polysaccharides in white leghorn cockerels. Proc Soc Exp Biol 123:321-326, 1966.
9. Parkinson TM, Gunderson K, Nelson NA: Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man. Atherosclerosis 11:531-537, 1970.
10. Fredrickson DS, Levy RI, Lees RS: Fat transport in lipoproteins: An integrated approach to mechanisms and disorders. New Eng J Med 276:32-44, 94-103, 148-156, 215-226, 273-281, 1967.
11. Fredrickson DS, Levy RI, Lindgren FT: A comparison of heritable abnormal lipoprotein patterns as defined by two different techniques. J Clin Invest 47:2446-2456, 1968.
12. Kessler G, Leder H: Fluorometric measurement of triglycerides, in Kress LT Jr (ed): Automation in Analytical Chemistry. New York, Mediad Inc, 1966, p 341.
13. Total cholesterol procedure, N-24, in Auto-Analyzer Manual. Chauncey, NY, Technicon Instruments Corp, 1964.
14. Fredrickson DS, Levy RI: Dietary management of hyperlipoproteinemia: Type II, publication 1667. Washington, DC, US Government Printing Office, 1969, p 395.
15. Choi Y, Kreines K: Effect of glycodiazine on blood sugar in diabetes mellitus. Diabetes 17:507-512, 1968.
16. Snedecor GW, Cochran WG: Two-way analysis of variance, in Statistical Methods, ed 6. Ames, Iowa, Iowa State College Press, 1967, pp 251, 299-338.
17. Gross L, Brotman M: Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. Ann Intern Med 72:95-96, 1970.
18. Goodman DS, Noble RP: Turnover of plasma cholesterol in man. J Clin Invest 47:231-241, 1968.
19. Moore RB, Crane CA, Frantz ID Jr. Effect of cholestyramine on fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient. J Clin Invest 47:1664-1671, 1968.
20. Langer J, Strober W, Levy RI: Familial Type II hyperlipoproteinemia: A defect of betalipoprotein apoprotein catabolism? J Clin Invest 48:49a, 1969.
21. Cohen MI, Winslow PR, Boley SJ: Intestinal obstruction associated with cholestyramine therapy. New Eng J Med 280:1285-1286, 1969.
22. Danhof IE: Effect of cholestyramine on fecal excretion of ingested radioiodinated lipids. Amer J Clin Nutr 18:343-349, 1966.
23. Gallo DG, Bailey KR, Sheffner AL: The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 120:60-65, 1965.
24. Northcutt RC, Stiel JN, Hollifield JW, et al: The influence of cholestyramine on thyroxine absorption. JAMA 208:1857-1861, 1969.
25. Weizel A, Estrich DL, Splitter SD, et al: Cholestyramine effect on plasma triglycerides in normolipidemic patients. Proc Soc Exp Biol Med 130:149-150, 1969.
26. Jones RJ, Dobrilovic L: Lipoprotein lipid alterations with cholestyramine administration. J Lab Clin Med 75:953-967, 1970.
27. Slack J: Risks of ischaemic heart-disease in familial hyperlipoproteinemic states. Lancet 2:1380-1382, 1969.
28. Quintao E, Grundy SM, Ahrens EH Jr. Effects of dietary cholesterol on the regulation of total body cholesterol in man. J Lipid Res 12:233-247, 1971.